ICCC Form 4: CEO option grant; total options now 150,260

Rhea-AI Filing Summary

ImmuCell Corp (ICCC) reported a Form 4 showing its President and CEO (also a Director) received a grant of 74,277 stock options at an exercise price of $6.10 on November 7, 2025.

The options vest in three equal tranches of 24,759 on the first, second, and third anniversaries of the grant and expire on November 7, 2035. The award will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified option. Following the grant, the officer beneficially owned 150,260 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider te Boekhorst Paul Francis Olivier

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	74,277	$6.10	$453K

Holdings After Transaction: Stock Options (right to buy) — 150,260 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

te Boekhorst Paul Francis Olivier

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND ME 04103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$6.1	11/07/2025	11/07/2025	A		74,277		(1)	11/07/2035	Common Stock	74,277	$6.1	150,260	D

Explanation of Responses:

1. Option grant made to Mr. te Boekhorst in connection with his commencement of employment as President and CEO. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 24,759 options on the first, second, and third anniversary of the grant date.

	/s/ Timothy C. Fiori Attorney-in-Fact	11/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ImmuCell (ICCC) disclose in this Form 4?

A grant of 74,277 stock options to its President and CEO at an exercise price of $6.10 on November 7, 2025.

What is the vesting schedule for the ICCC CEO option grant?

The options vest 24,759 on each of the first, second, and third anniversaries of the November 7, 2025 grant.

When do the newly granted ICCC options expire?

The options expire on November 7, 2035.

How are the ICCC CEO’s options classified for tax purposes?

They will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified stock option.

How many derivative securities does the ICCC officer own after this grant?

Following the grant, the officer beneficially owned 150,260 derivative securities.

What is the exercise price of the ICCC CEO’s new options?

The exercise price is $6.10 per share.